C-12蛋白芯片检测系统在消化道恶性肿瘤诊断中应用价值.doc

C-12蛋白芯片检测系统在消化道恶性肿瘤诊断中应用价值 　【摘要】 目的 研究多肿瘤标志物蛋白芯片在消化道恶性肿瘤诊断中的应用价值。方法 采用C-12蛋白芯片检测系统检测283例消化道恶性肿瘤患者(恶性肿瘤组)、186例消化道良性疾病患者(良性疾病组)和421例正常对照者(正常对照组)血清中12种肿瘤标志物的表达水平。结果 恶性肿瘤组的阳性率为77.74%,显著高于良性疾病组(35.48%, Plt;0.01)和正常对照组(22.09%，Plt;0.01)。该蛋白芯片对消化道恶性肿瘤检测的灵敏度为77.74%，特异度为73.81%，准确率为75.06%，阳性预测值为58.05%，阴性预测值为87.67%;联合检测的阳性率均显著高于单一标志物检测(Plt;0.05), 但是联合检测对临床Ⅰ、Ⅱ期消化道恶性肿瘤的阳性率仍然偏低，为30.16%;癌胚抗原(CEA)、CA19-9、CA242、CA15-3、CA125、铁蛋白在消化道恶性肿瘤中的表达明显强于其他标志物(Plt;0.05)。结论 C-12蛋白芯片检测系统监测病情和判断预后的价值优于诊断价值,但是用于消化道恶性肿瘤的早期诊断灵敏度不高。建议利用近年来血清肿瘤标志物研究的最新成果，对现有指标进行优化组合，推出一款专门针对消化道恶性肿瘤的蛋白芯片，以提高其检测效果和早期诊断率。 【关键词】 消化道恶性肿瘤;肿瘤标志物;蛋白芯片;早期诊断 　　Abstract: Objective To investigate the application value of C-12 protein biochip detective system in the diagnosis of digestive tract malignancies. Methods The expression of twelve tumor markers in serum were detected by protein biochip technology in 283 cases of malignant tumor of digestive tract cancer, 186 cases of benign digestive diseases and 421 cases of normal control. Results The positive ratio of 77.74% in the malignant tumor group was significantly higher than that of the benign diseases group (35.48%, Plt;0.01) and the normal control group (22.09%, Plt;0.01). The sensitivity, specificity, accuracy, positive predictive value and negative predictive value of the protein biochip system were 77.74%, 73.81%, 75.06%, 58.05%, and 87.67%, respectively. The positive ratio of combined detection was significantly higher than that of single tumor maker (Plt;0.05), but its positive ratio of 30.16% for staging Ⅰ and Ⅱ digestive tract cancer was still relatively low. The expression of tumor markers CEA, CA19-9, CA242, CA15-3, CA125 and ferrtin in digestive tract cancer was markedly stronger than the others (Plt;0.05). Conclusions The effect of C-12 protein biochip detection system on illness monitoring and prognosis judgment was better than that on diagnosis, but it had less sensitivity for the early diagnosis of digestive tract cancer. It is preferable that the existing indi